Navigation Links
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Date:1/31/2008

e mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (ie, bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON(TM). Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON(TM).

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON(TM) but similar to INTRON(R) A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON(TM).

The following serious or clinically significant adverse events have been reported at a frequency less than or equal to 1% with PEGINTRON(TM) or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

Additional Safety Information

Relapse of drug addiction/overdose has occurred in patients on PEGINTRON(TM) therapy. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON(TM) and/or INTRON(R) A treatment and follow-up.

If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON(TM) and
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... announced the launch of several innovative new programs to ... the current economic climate. The first is aimed ... legal services over a period of 6, 12, 18, ... start-up companies. The second is aimed at more ... over 6 to 12 month period at discounted rates, ...
(Date:12/14/2009)... International, Inc. (Pink Sheets: DYAI) ("Dyadic") announced today ... Scripps Research Institute ("Scripps") by entering into an ... Dyadic,s patented and proprietary C1 fungus ("C1"). ,, ... relationship between the two organizations which began in ... the C1 genome for the first time. The ...
(Date:12/14/2009)... Boston Scientific Corporation (NYSE: BSX ... of $2 billion aggregate principal amount of its senior ... public offering consists of $850 million of 4.50 percent ... notes due January 2020 and $300 million of 7.375 ... to use the net proceeds for general corporate purposes, ...
(Date:12/14/2009)... Dec. 14 Decision Resources, one of ... pharmaceutical and healthcare issues, finds that, owing to ... fibrillation drug market will increase more than sevenfold ... in 2018 in the United States, France, Germany, ... The new Pharmacor report entitled Atrial Fibrillation ...
Breaking Biology Technology:The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2
... BOTHELL, Wash., June 4 CellCyte Genetics,Corporation,s (CellCyte) (OTC ... present at the 2008 San Francisco RedChip Small-Cap Investor,Conference ... Time at the,Palace Hotel in San Francisco. In addition, ... they will have a prototype demonstration of the,Company,s cell ...
... plan designed to develop,educational opportunities for students in ... Center (TWLC) are collaborating to pilot a,novel approach ... National,Research Council studied the declining interest in science ... increased scientific interests if they are,able to participate ...
... 4 In response to numerous,shareholder questions, CEL-SCI ... on the construction of its manufacturing facility near ... comprise 73,000 square,feet and will be used to ... facility will produce the Multikine that,will be used ...
Other Biology Technology:LI-COR(R) Biosciences and Tiger Woods Learning Center Collaborate to Develop High School Curriculum in Genetics 2CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter 2CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter 3
(Date:12/14/2009)... clean-burning, renewable fuel that could help wean the nation ... ozone, compared with gasoline, especially in winter, according to ... Ozone production from both gasoline and E85, a blend ... is greater in warm sunny weather than during the ... and sunlight contribute to ozone formation. But E85 produces ...
(Date:12/14/2009)... INDIANAPOLIS The most comprehensive study to date of ... regrow appendages may provide important clues to how similar ... at the School of Science at Indiana University-Purdue University ... the amputated limbs of axolotls, a type of salamander ... from any level of amputation, with the hope that ...
(Date:12/14/2009)... feature of humans. That,s until examples of tool use came ... of other mammals. Now, a report in the December 14th ... adds an octopus to the growing list of tool users. ... that the researchers call stilt walking. In it, the soft-bodied ... its eight arms rigid, and raises the whole assembly to ...
Breaking Biology News(10 mins):Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3IUPUI researchers tackle protein mechanisms behind limb regeneration 2Tool use in an invertebrate: The coconut-carrying octopus 2Extinct moa rewrites New Zealands history 10782 1Extinct moa rewrites New Zealands history 10782 2Heart Failure Drug May Help More in Higher Doses 61609 1Heart Failure Drug May Help More in Higher Doses 61609 2Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment 61605 1Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment 61605 2
... Project and other studies linking human DNA to that of ... powerful evidence of evolution in DNA. Professor and research geneticist ... evolution found in the DNA of every person on the ... IN HUMAN DNA (Prometheus Books, $24.95). , This book comes ...
... the long-sought telomerase RNA gene in a single-cell research ... site of the journal Nature Structural & Molecular Biology ... , Chromosomes shorten with every cell division. In stem ... by telomerase, an enzyme that adds short repeat sequences ...
... nations pre-eminent genetic researchers, Eric Hoffman, PhD, of ... predicts that in relatively short order, medicines next ... treat muscular dystrophies, and other disorders. ... England Journal of Medicine, Dr. Hoffman posits that ...
Other Biology News:There is powerful evidence of evolution in human DNA 2Baumann lab identifies elusive telomere RNA subunit in single cell model 2New clinical trial results show how personalized medicine will alter treatment of genetic disorders 2
... JAK2 (phospho Y1007) ( Abpromise ... Antigen: Synthesized phosphopeptide derived ... site of tyrosine 1007 (K-E-Y P ... ID: 3717 ...
Harmful, Irritant, Combustible ,DEPC...
Permeabilization Solution, 5X...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Biology Products: